The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Top Cited Papers
Open Access
- 20 August 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (5) , 1577-1586
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is uncertainty around the economic burden of NAFLD. We constructed a steady‐state prevalence model to quantify this burden in the United States and Europe. Five models were constructed to estimate the burden of NAFLD in the United States and four European countries. Models were built using a series of interlinked Markov chains, each representing age increments of the NAFLD and the general populations. Incidence and remission rates were calculated by calibrating against real‐world prevalence rates. The data were validated using a computerized disease model called DisMod II. NAFLD patients transitioned between nine health states (nonalcoholic fatty liver, nonalcoholic steatohepatitis [NASH], NASH‐fibrosis, NASH‐compensated cirrhosis, NASH‐decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, post‐liver transplant, and death). Transition probabilities were sourced from the literature and calibrated against real‐world data. Utilities were obtained from NAFLD patients using the Short Form‐6D. Costs were sourced from the literature and local fee schedules. In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient). In the Europe‐4 countries (Germany, France, Italy, and United Kingdom), there are ∼52 million people with NAFLD with an annual cost of about €35 billion (from €354 to €1,163 per patient). Costs are highest in patients aged 45‐65. The burden is significantly higher when societal costs are included. Conclusion: The analysis quantifies the enormity of the clinical and economic burdens of NAFLD, which will likely increase as the incidence of NAFLD continues to rise. (Hepatology 2016;64:1577‐1586)Keywords
Funding Information
- Gilead Sciences
This publication has 42 references indexed in Scilit:
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CHepatology, 2011
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortalityHepatology, 2011
- Calibrating Models in Economic EvaluationPharmacoEconomics, 2011
- Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty ConnectionHepatology, 2010
- Spanish recommendations on economic evaluation of health technologiesThe European Journal of Health Economics, 2010
- Long-Term Improvement in Health-Related Quality of Life After Orthotopic Liver TransplantationLiver Transplantation, 2008
- Cardiovascular Risk Factors and the Metabolic Syndrome in Pediatric Nonalcoholic Fatty Liver DiseaseCirculation, 2008
- Systematic Review: Health-State Utilities in Liver Disease: A Systematic ReviewMedical Decision Making, 2008
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006
- Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type CJournal of Hepatology, 1997